新型口服抗凝药物预防房颤血栓栓塞的研究进展

Research progress of new oral anticoagulants for prevention of atrial fibrillation thromboembolism

心房颤动(房颤)是缺血性脑卒中的强危险因素。华法林的一些缺陷使临床应用受到一定的限制,从而加速了新型口服抗凝药物达比加群、阿哌沙班、利伐沙班、依杜沙班等的研发。本文对此研究进展作一综述。

Atrial fibrillation （AF）is a strong risk factor for ischemic cerebral stroke.Some inherent defects of Warfarin limit its clinic application,which accelerates research and development of new oral anticoagulants,such as Dabigatran,Apixaban,Rivaroxaban and Edoxaban etc..This article made an overview for these.